Published in Clin Cancer Res on April 01, 2002
Molecular genetics of prostate cancer: new prospects for old challenges. Genes Dev (2010) 5.83
Targeting AKT/mTOR and ERK MAPK signaling inhibits hormone-refractory prostate cancer in a preclinical mouse model. J Clin Invest (2008) 4.13
Targeting the PI3K/Akt/mTOR pathway: effective combinations and clinical considerations. Drug Resist Updat (2007) 3.78
An oncogene-tumor suppressor cascade drives metastatic prostate cancer by coordinately activating Ras and nuclear factor-kappaB. Nat Med (2010) 3.09
Incidence, mechanism and prognostic value of activated AKT in pancreas cancer. Br J Cancer (2003) 2.03
Impact of circulating cholesterol levels on growth and intratumoral androgen concentration of prostate tumors. PLoS One (2012) 1.89
Combinatorial activities of Akt and B-Raf/Erk signaling in a mouse model of androgen-independent prostate cancer. Proc Natl Acad Sci U S A (2006) 1.78
Antagonists of growth hormone-releasing hormone inhibit growth of androgen-independent prostate cancer through inactivation of ERK and Akt kinases. Proc Natl Acad Sci U S A (2012) 1.69
Targeted therapy for advanced prostate cancer: inhibition of the PI3K/Akt/mTOR pathway. Curr Cancer Drug Targets (2009) 1.66
Retracted Psoralidin, an herbal molecule, inhibits phosphatidylinositol 3-kinase-mediated Akt signaling in androgen-independent prostate cancer cells. Cancer Prev Res (Phila) (2009) 1.57
Expression and localisation of Akt-1, Akt-2 and Akt-3 correlate with clinical outcome of prostate cancer patients. Br J Cancer (2006) 1.47
New developments in the medical management of prostate cancer. Mayo Clin Proc (2010) 1.41
Wild carrot pentane-based fractions suppress proliferation of human HaCaT keratinocytes and protect against chemically-induced skin cancer. BMC Complement Altern Med (2017) 1.39
Akt/cAMP-responsive element binding protein/cyclin D1 network: a novel target for prostate cancer inhibition in transgenic adenocarcinoma of mouse prostate model mediated by Nexrutine, a Phellodendron amurense bark extract. Clin Cancer Res (2007) 1.29
Increased expression of pAKT is associated with radiation resistance in cervical cancer. Br J Cancer (2006) 1.28
Targeting prostate cancer based on signal transduction and cell cycle pathways. Cell Cycle (2008) 1.25
Phosphorylation of the androgen receptor is associated with reduced survival in hormone-refractory prostate cancer patients. Br J Cancer (2008) 1.24
Apoptosis evasion: the role of survival pathways in prostate cancer progression and therapeutic resistance. J Cell Biochem (2006) 1.22
Expression and prognostic relevance of activated extracellular-regulated kinases (ERK1/2) in breast cancer. Br J Cancer (2005) 1.22
miR-331-3p regulates ERBB-2 expression and androgen receptor signaling in prostate cancer. J Biol Chem (2009) 1.19
Tumor suppressor activity of the ERK/MAPK pathway by promoting selective protein degradation. Genes Dev (2013) 1.18
Phospho-Akt immunoreactivity in prostate cancer: relationship to disease severity and outcome, Ki67 and phosphorylated EGFR expression. PLoS One (2012) 1.14
MicroRNA miR-125a-3p modulates molecular pathway of motility and migration in prostate cancer cells. Oncoscience (2014) 1.10
Modulation of protein phosphatase 2A activity alters androgen-independent growth of prostate cancer cells: therapeutic implications. Mol Cancer Ther (2011) 1.10
Prognostic value of activated Akt expression in oral squamous cell carcinoma. J Clin Pathol (2005) 1.07
Lkb1 and Pten synergise to suppress mTOR-mediated tumorigenesis and epithelial-mesenchymal transition in the mouse bladder. PLoS One (2011) 1.06
MAP Kinases and Prostate Cancer. J Signal Transduct (2011) 1.06
Membrane-type 1 matrix metalloproteinase is regulated by sp1 through the differential activation of AKT, JNK, and ERK pathways in human prostate tumor cells. Neoplasia (2007) 1.04
Prediction of prostate cancer recurrence using magnetic resonance imaging and molecular profiles. Clin Cancer Res (2009) 1.03
REST mediates androgen receptor actions on gene repression and predicts early recurrence of prostate cancer. Nucleic Acids Res (2013) 1.02
Integrin signaling aberrations in prostate cancer. Am J Transl Res (2009) 1.01
The CXCL12/CXCR4 axis promotes ligand-independent activation of the androgen receptor. Mol Cell Endocrinol (2012) 1.01
4-Hydroxy-3-methoxybenzoic acid methyl ester: a curcumin derivative targets Akt/NF kappa B cell survival signaling pathway: potential for prostate cancer management. Neoplasia (2003) 1.00
miRNA-34b inhibits prostate cancer through demethylation, active chromatin modifications, and AKT pathways. Clin Cancer Res (2012) 1.00
Akt1/protein kinase B alpha is involved in gastric cancer progression and cell proliferation. Dig Dis Sci (2008) 0.99
Neurofibromatosis type 1-related gastrointestinal stromal tumors: a special reference to loss of heterozygosity at 14q and 22q. J Cancer Res Clin Oncol (2008) 0.99
Receptor-recognized α₂-macroglobulin binds to cell surface-associated GRP78 and activates mTORC1 and mTORC2 signaling in prostate cancer cells. PLoS One (2012) 0.98
Elevated AKR1C3 expression promotes prostate cancer cell survival and prostate cell-mediated endothelial cell tube formation: implications for prostate cancer progression. BMC Cancer (2010) 0.97
Dietary flavonoid fisetin: a novel dual inhibitor of PI3K/Akt and mTOR for prostate cancer management. Biochem Pharmacol (2012) 0.94
Prostate cancer stem cells: deciphering the origins and pathways involved in prostate tumorigenesis and aggression. Oncotarget (2015) 0.93
Akt activation is a common event in pediatric malignant gliomas and a potential adverse prognostic marker: a report from the Children's Oncology Group. J Neurooncol (2010) 0.93
Increased level of phosphorylated akt measured by chemiluminescence-linked immunosorbent assay is a predictor of poor prognosis in primary breast cancer overexpressing ErbB-2. Breast Cancer Res (2005) 0.92
Genetic variations in a PTEN/AKT/mTOR axis and prostate cancer risk in a Chinese population. PLoS One (2012) 0.91
Extra-cellular signal-regulated ERK-1/ERK-2 pathway activation in human salivary gland mucoepidermoid carcinoma: association to aggressive tumor behavior and tumor cell proliferation. Am J Pathol (2003) 0.91
AKT3 promotes prostate cancer proliferation cells through regulation of Akt, B-Raf, and TSC1/TSC2. Oncotarget (2015) 0.91
Saposin C promotes survival and prevents apoptosis via PI3K/Akt-dependent pathway in prostate cancer cells. Mol Cancer (2004) 0.91
AKT in cancer: new molecular insights and advances in drug development. Br J Clin Pharmacol (2016) 0.90
Modulators of prostate cancer cell proliferation and viability identified by short-hairpin RNA library screening. PLoS One (2012) 0.90
Loss of PTEN stabilizes the lipid modifying enzyme cytosolic phospholipase A₂α via AKT in prostate cancer cells. Oncotarget (2014) 0.90
Increased staining for phospho-Akt, p65/RELA and cIAP-2 in pre-neoplastic human bronchial biopsies. BMC Cancer (2005) 0.90
The Par-4/PTEN connection in tumor suppression. Cell Cycle (2009) 0.90
Quantitative in situ detection of phosphoproteins in fixed tissues using quantum dot technology. J Histochem Cytochem (2009) 0.89
Loss of EGFR signaling regulated miR-203 promotes prostate cancer bone metastasis and tyrosine kinase inhibitors resistance. Oncotarget (2014) 0.88
Morphoproteomic confirmation of a constitutively activated mTOR pathway in high grade prostatic intraepithelial neoplasia and prostate cancer. Int J Clin Exp Pathol (2008) 0.87
Restoration of PTEN expression alters the sensitivity of prostate cancer cells to EGFR inhibitors. Prostate (2008) 0.87
CD24 expression is an independent prognostic marker in cholangiocarcinoma. J Gastrointest Surg (2007) 0.87
Protocadherin-PC promotes androgen-independent prostate cancer cell growth. Prostate (2006) 0.86
Sphingosine kinase-1 is central to androgen-regulated prostate cancer growth and survival. PLoS One (2009) 0.86
Correlation of MR imaging and MR spectroscopic imaging findings with Ki-67, phospho-Akt, and androgen receptor expression in prostate cancer. Radiology (2009) 0.85
A Functional Polymorphism (rs2494752) in the AKT1 Promoter Region and Gastric Adenocarcinoma Risk in an Eastern Chinese Population. Sci Rep (2016) 0.85
AGE/RAGE/Akt pathway contributes to prostate cancer cell proliferation by promoting Rb phosphorylation and degradation. Am J Cancer Res (2015) 0.84
Dual modulation of JNK and Akt signaling pathways by chaetoglobosin K in human lung carcinoma and ras-transformed epithelial cells. Invest New Drugs (2012) 0.83
Dose dependent activation of retinoic acid-inducible gene-I promotes both proliferation and apoptosis signals in human head and neck squamous cell carcinoma. PLoS One (2013) 0.83
1,4-phenylenebis(methylene)selenocyanate, but not selenomethionine, inhibits androgen receptor and Akt signaling in human prostate cancer cells. Cancer Prev Res (Phila) (2010) 0.82
E3 ubiquitin protein ligase, E6-associated protein (E6-AP) regulates PI3K-Akt signaling and prostate cell growth. Biochim Biophys Acta (2010) 0.81
Castration-resistant prostate cancer: new science and therapeutic prospects. Ther Adv Med Oncol (2010) 0.80
Rationally designed treatment for solid tumors with MAPK pathway activation: a phase I study of paclitaxel and bortezomib using an adaptive dose-finding approach. Mol Cancer Ther (2011) 0.80
TMEFF2 modulates the AKT and ERK signaling pathways. Int J Biochem Mol Biol (2013) 0.80
The prognostic value of phosphorylated AKT expression in non-small cell lung cancer: a meta-analysis. PLoS One (2013) 0.79
Sensitivity and mechanisms of taxol-resistant prostate adenocarcinoma cells to Vernonia amygdalina extract. Exp Toxicol Pathol (2012) 0.79
Measuring PI3K Activation: Clinicopathologic, Immunohistochemical, and RNA Expression Analysis in Prostate Cancer. Mol Cancer Res (2015) 0.79
Overexpression of Endoplasmic Reticulum Oxidoreductin 1-α (ERO1L) Is Associated with Poor Prognosis of Gastric Cancer. Cancer Res Treat (2016) 0.79
Targeting key signalling pathways in oesophageal adenocarcinoma: a reality for personalised medicine? World J Gastroenterol (2011) 0.78
Expression of cellular components in granulomatous inflammatory response in Piaractus mesopotamicus model. PLoS One (2015) 0.77
Activation of Akt at T308 and S473 in alcohol, tobacco and HPV-induced HNSCC: is there evidence to support a prognostic or diagnostic role? Exp Hematol Oncol (2014) 0.77
Reciprocal feedback inhibition of the androgen receptor and PI3K as a novel therapy for castrate-sensitive and -resistant prostate cancer. Oncotarget (2015) 0.77
Relationship between tumour PTEN/Akt/COX-2 expression, inflammatory response and survival in patients with colorectal cancer. Oncotarget (2016) 0.77
The importance of non-nuclear AR signaling in prostate cancer progression and therapeutic resistance. Cell Signal (2016) 0.77
Association between cannabinoid CB₁ receptor expression and Akt signalling in prostate cancer. PLoS One (2013) 0.77
Signaling mechanisms coupled to CXCL12/CXCR4-mediated cellular proliferation are PTEN-dependent. Am J Clin Exp Urol (2015) 0.76
A Cell-Cell Communication Marker for Identifying Targeted Tumor Therapies. Curr Bioact Compd (2013) 0.76
Immunohistochemical Assessment of Phosphorylated mTORC1-Pathway Proteins in Human Brain Tumors. PLoS One (2015) 0.75
Pathogenesis of prostate cancer and hormone refractory prostate cancer. Indian J Urol (2007) 0.75
The role of chemotherapy and new targeted agents in the management of primary prostate cancer. J Clin Urol (2016) 0.75
Skp2 regulates subcellular localization of PPARγ by MEK signaling pathways in human breast cancer. Int J Mol Sci (2013) 0.75
Combined AKT and MEK Pathway Blockade in Pre-Clinical Models of Enzalutamide-Resistant Prostate Cancer. PLoS One (2016) 0.75
Akt Activation Correlates with Snail Expression and Potentially Determines the Recurrence of Prostate Cancer in Patients at Stage T2 after a Radical Prostatectomy. Int J Mol Sci (2016) 0.75
Phase II trial of temsirolimus (CCI-779) in recurrent glioblastoma multiforme: a North Central Cancer Treatment Group Study. J Clin Oncol (2005) 3.50
Multiple primary malignant neoplasms: case report and a comprehensive review of the literature. Am J Clin Oncol (2003) 2.29
Phosphorylation of Akt (Ser473) is an excellent predictor of poor clinical outcome in prostate cancer. Cancer Res (2004) 2.15
External validation of the Prostate Cancer Prevention Trial risk calculator in a screened population. Urology (2006) 2.05
Pharmacodynamic evaluation of the epidermal growth factor receptor inhibitor OSI-774 in human epidermis of cancer patients. Clin Cancer Res (2003) 1.82
Determining risk of biochemical recurrence in prostate cancer by immunohistochemical detection of PTEN expression and Akt activation. Clin Cancer Res (2007) 1.66
Signal transduction pathways in androgen-dependent and -independent prostate cancer cell proliferation. Endocr Relat Cancer (2005) 1.43
Trichostatin A induces transforming growth factor beta type II receptor promoter activity and acetylation of Sp1 by recruitment of PCAF/p300 to a Sp1.NF-Y complex. J Biol Chem (2005) 1.35
Cross-talk between the androgen receptor and the phosphatidylinositol 3-kinase/Akt pathway in prostate cancer. Curr Cancer Drug Targets (2007) 1.34
Akt/cAMP-responsive element binding protein/cyclin D1 network: a novel target for prostate cancer inhibition in transgenic adenocarcinoma of mouse prostate model mediated by Nexrutine, a Phellodendron amurense bark extract. Clin Cancer Res (2007) 1.29
The chemokine CXCL16 and its receptor, CXCR6, as markers and promoters of inflammation-associated cancers. PLoS One (2009) 1.29
Nuclear versus cytoplasmic localization of filamin A in prostate cancer: immunohistochemical correlation with metastases. Clin Cancer Res (2009) 1.20
Brief psychiatric rating scale expanded version: How do new items affect factor structure? Psychiatry Res (2005) 1.14
A novel mechanism of resistance to epidermal growth factor receptor antagonism in vivo. Cancer Res (2007) 1.13
Akt in prostate cancer: possible role in androgen-independence. Curr Drug Metab (2003) 1.13
Association of RNASEL variants with prostate cancer risk in Hispanic Caucasians and African Americans. Clin Cancer Res (2007) 1.11
MALDI imaging mass spectrometry profiling of proteins and lipids in clear cell renal cell carcinoma. Proteomics (2014) 1.10
Identification of differentially expressed proteins in direct expressed prostatic secretions of men with organ-confined versus extracapsular prostate cancer. Mol Cell Proteomics (2012) 1.08
Epidermal growth factor receptor expression correlates with histologic grade in resected esophageal adenocarcinoma. J Gastrointest Surg (2004) 1.08
Differential effects of p21(WAF1/CIP1) deficiency on MMTV-ras and MMTV-myc mammary tumor properties. Cancer Res (2002) 1.04
Smad4-dependent TGF-beta signaling suppresses RON receptor tyrosine kinase-dependent motility and invasion of pancreatic cancer cells. J Biol Chem (2008) 1.02
Regulation of Cox-2 by cyclic AMP response element binding protein in prostate cancer: potential role for nexrutine. Neoplasia (2007) 1.01
Direct and efficient cellular transformation of primary rat mesenchymal precursor cells by KSHV. J Clin Invest (2012) 1.01
Dual EGFR/HER2 inhibition sensitizes prostate cancer cells to androgen withdrawal by suppressing ErbB3. Clin Cancer Res (2011) 0.99
MALDI tissue imaging: from biomarker discovery to clinical applications. Anal Bioanal Chem (2011) 0.98
Statins and prostate cancer: role of cholesterol inhibition vs. prevention of small GTP-binding proteins. Am J Cancer Res (2011) 0.97
Identification of prostate-enriched proteins by in-depth proteomic analyses of expressed prostatic secretions in urine. J Proteome Res (2012) 0.97
Targeting ErbB3: the New RTK(id) on the Prostate Cancer Block. Immunol Endocr Metab Agents Med Chem (2011) 0.97
Involvement of FLIP in 2-methoxyestradiol-induced tumor regression in transgenic adenocarcinoma of mouse prostate model. Clin Cancer Res (2009) 0.97
The dual role of filamin A in cancer: can't live with (too much of) it, can't live without it. Endocr Relat Cancer (2013) 0.96
Genome-wide analysis of androgen receptor binding and gene regulation in two CWR22-derived prostate cancer cell lines. Endocr Relat Cancer (2010) 0.95
RhoA-dependent murine prostate cancer cell proliferation and apoptosis: role of protein kinase Czeta. Cancer Res (2002) 0.93
Cytoskeletal rearrangement and signal transduction in TGF-beta1-stimulated mesangial cell collagen accumulation. J Am Soc Nephrol (2003) 0.93
Detection of recurrent copy number loss at Yp11.2 involving TSPY gene cluster in prostate cancer using array-based comparative genomic hybridization. Cancer Res (2006) 0.91
Dietary resveratrol prevents development of high-grade prostatic intraepithelial neoplastic lesions: involvement of SIRT1/S6K axis. Cancer Prev Res (Phila) (2012) 0.90
The effects of epidermal growth factor receptor activation and attenuation of the TGFbeta pathway in an orthotopic model of colon cancer. J Surg Res (2009) 0.90
Combined targeting of STAT3/NF-κB/COX-2/EP4 for effective management of pancreatic cancer. Clin Cancer Res (2014) 0.90
Cancer detection and biopsy classification using concurrent histopathological and metabolomic analysis of core biopsies. Genome Med (2012) 0.90
Nrdp1-mediated regulation of ErbB3 expression by the androgen receptor in androgen-dependent but not castrate-resistant prostate cancer cells. Cancer Res (2010) 0.90
Alternative spliced variants of the alpha-methylacyl-CoA racemase gene and their expression in prostate cancer. Gene (2004) 0.88
AKT regulates androgen receptor-dependent growth and PSA expression in prostate cancer. Adv Exp Med Biol (2008) 0.88
Role of protein kinase C in arginine vasopressin-stimulated ERK and p70S6 kinase phosphorylation. J Cell Biochem (2004) 0.88
Enhancing the effectiveness of androgen deprivation in prostate cancer by inducing Filamin A nuclear localization. Endocr Relat Cancer (2012) 0.85
Molecular preservation by extraction and fixation, mPREF: a method for small molecule biomarker analysis and histology on exactly the same tissue. BMC Clin Pathol (2011) 0.85
Phase I, pharmacokinetic, and biological study of erlotinib in combination with paclitaxel and carboplatin in patients with advanced solid tumors. Clin Cancer Res (2006) 0.84
beta-Adrenergic-responsive activation of extracellular signal-regulated protein kinases in salivary cells: role of epidermal growth factor receptor and cAMP. Am J Physiol Cell Physiol (2005) 0.84
A variant of the alpha-methyl-acyl-CoA racemase gene created by a deletion in exon 5 and its expression in prostate cancer. Prostate (2005) 0.83
Androgen Receptor regulation of Vitamin D receptor in response of castration-resistant prostate cancer cells to 1α-Hydroxyvitamin D5 - a calcitriol analog. Genes Cancer (2010) 0.82
Nonhuman primates as models for studies of prostate specific antigen and prostatic diseases. Prostate (2008) 0.82
Androgen receptor length polymorphism associated with prostate cancer risk in Hispanic men. J Urol (2002) 0.82
Prostate cancer risk with positive family history, normal prostate examination findings, and PSA less than 4.0 ng/mL. Urology (2007) 0.82
Using boronolectin in MALDI-MS imaging for the histological analysis of cancer tissue expressing the sialyl Lewis X antigen. Chem Commun (Camb) (2011) 0.81
Differences in sensitivity of biological functions mediated by epidermal growth factor receptor activation with respect to endogenous and exogenous ligands. J Biol Chem (2001) 0.81
Dual blockade of PKA and NF-κB inhibits H2 relaxin-mediated castrate-resistant growth of prostate cancer sublines and induces apoptosis. Horm Cancer (2011) 0.81
Expression profiling identifies a novel alpha-methylacyl-CoA racemase exon with fumarate hydratase homology. Cancer Res (2003) 0.80
Intestinal trefoil factor (TFF-3) and extracellular signal-regulated kinase (ERK) in cholangiocarcinoma. Hepatogastroenterology (2007) 0.80
p53-independent response to cisplatin and oxaliplatin in MMTV-ras mouse salivary tumors. Mol Cancer Ther (2003) 0.80
Association of polymorphisms in TGFB1 and prostate cancer prognosis. J Urol (2007) 0.80
The modulation of prostate cancer risk with alpha-tocopherol: a pilot randomized, controlled clinical trial. J Urol (2005) 0.79
Effect of the antitumor drug vinblastine on nuclear betaII-tubulin in cultured rat kidney mesangial cells. Invest New Drugs (2003) 0.79
Multiple recognition assay reveals prostasomes as promising plasma biomarkers for prostate cancer. Expert Rev Anticancer Ther (2011) 0.79
Lovastatin inhibits oxidized L-A-phosphatidylcholine B-arachidonoyl-gamma-palmitoyl (ox-PAPC)-stimulated interleukin-8 mRNA and protein synthesis in human aortic endothelial cells by depleting stores of geranylgeranyl pyrophosphate. Atherosclerosis (2009) 0.78
A preliminary study of the baboon prostate pathophysiology. Prostate (2007) 0.78
The changing roles of steroid nuclear receptors with prostate cancer progression. Endocr Relat Cancer (2013) 0.78
Reduced expression of epidermal growth factor receptors in rat liver during aging. J Gerontol A Biol Sci Med Sci (2008) 0.78
Semaphorin 3B and 3F single nucleotide polymorphisms are associated with prostate cancer risk and poor prognosis. J Urol (2009) 0.77
The effects of high frequency, low intensity ultrasound therapy on parotid flow rates. Oral Surg Oral Med Oral Pathol Oral Radiol Endod (2008) 0.77
The role of transforming growth factor-beta in suppression of hepatic metastasis from colon cancer. HPB (Oxford) (2010) 0.77
Linking inflammation and neuroendocrine differentiation: the role of macrophage migration inhibitory factor-mediated signaling in prostate cancer. Endocr Relat Cancer (2013) 0.76
Professional Caregivers' Oral Care Practices and Beliefs for Elderly Clients Aging In Place. J Dent Hyg (2016) 0.75
Histologic Grading of Prostatic Adenocarcinoma Can Be Further Optimized: Analysis of the Relative Prognostic Strength of Individual Architectural Patterns in 1275 Patients From the Canary Retrospective Cohort. Am J Surg Pathol (2016) 0.75
Immunohistochemical determination of EGFR-tyrosine kinase inhibition in clinical samples. Methods Mol Med (2003) 0.75